Royalty Pharma plc
RPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.55 | 0.00 | -4.33 | -0.66 |
| FCF Yield | 24.34% | 23.76% | 12.39% | 12.21% |
| EV / EBITDA | 11.60 | 9.66 | 53.61 | 15.44 |
| Quality | ||||
| ROIC | 7.19% | 9.20% | 1.84% | 8.25% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 2.08 | 1.76 | 9.32 | 1.63 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.39% | 0.94% | 1.77% | 8.06% |
| Free Cash Flow Growth | -7.32% | 39.36% | 6.27% | -0.84% |
| Safety | ||||
| Net Debt / EBITDA | 4.29 | 3.00 | 12.76 | 3.88 |
| Interest Coverage | 5.73 | 7.97 | 1.63 | 8.61 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 4.35 | 3.47 | 5.97 | 10.89 |